Netherlands-based AMT Medical, a medtech innovator, has secured €22M in a Series B funding round. The company looks to accelerate the development and commercialisation of its heart bypass technology.
The round includes a €5M investment from Invest-NL, a Dutch impact investor focused on driving innovation in the Netherlands.
The Series B round was led by Bender Analytical Holding and joined by Oost NL, the European Innovation Council (EIC), and a group of informal investors.
Making heart bypass surgery safer
Founded in 2015, AMT Medical is a medtech company developing a new approach to coronary artery bypass surgery. The company’s Elana Heart Bypass technology enables bypass procedures without opening the chest or stopping the heart. Using a patented clip and laser system, it connects blood vessels without the need for stitches.
The technology is compatible with surgical robots and supports standardised, minimally invasive procedures. This approach expands treatment options to a broader group of patients, including those who are not eligible for traditional open-heart surgery.
AMT’s method aims to reduce surgical risks and shorten recovery time, allowing patients to return home within days. The technique was developed in partnership with UMC Utrecht and is currently being applied in clinical settings at Antonius Hospital Nieuwegein and the German Heart Centre in Berlin.
The company collaborates closely with medical specialists, advisors, and investors to establish its procedure as a new standard in bypass surgery.
Koen van Breugel, senior investment manager at Invest-NL, says, “We see AMT as a game changer that not only improves patient outcomes, but also reduces the pressure on the healthcare system.”
“This technology makes minimally invasive cardiac surgery more accessible, safer and scalable – exactly the kind of system innovation we believe in.”
Capital utilisation
The financing from Invest-NL will support AMT Medical in obtaining CE marking, carrying out clinical studies in the Netherlands and other countries, and preparing for entry into the market.
The investment aligns with Invest-NL’s aim to support the long-term sustainability of the healthcare system in terms of cost, staffing, and access.
Initial results from current clinical research are expected by the end of 2025.
01
Celebrating 20 years of driving ‘High-Tech’ innovation: Berlin to host HTGF Family Day 2025; 4 reasons to join